CAPRICOR THERAPEUTICS, INC. 8-K

What Happened
Capricor Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 in a press release issued May 12, 2026. The company filed a Form 8‑K (Item 2.02) to furnish that press release and disclose its results of operations and financial condition for Q1 2026.

Key Details

• The press release is furnished as Exhibit 99.1 to the Form 8‑K and is titled “Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update” (dated May 12, 2026).
• The filing covers results for the quarter ended March 31, 2026 (first quarter 2026).
• The Form 8‑K also includes the Cover Page Interactive Data File (inline XBRL) as Exhibit 104.
• The report was signed and filed by Linda Marbán, Ph.D., Chief Executive Officer, on May 12, 2026.

Why It Matters
This 8‑K puts Capricor’s latest quarterly results and corporate update into the public record, giving investors access to the company’s recent operating and financial information. The furnished press release and inline XBRL data allow shareholders and analysts to review the company’s reported quarterly performance (earnings, revenue, cash position, or other financial metrics shown in the release) and incorporate that information into valuation, trading, or investment decisions.